Adjuvant mitozantrone chemotherapy in advanced prostate cancer
Authors:
Open Access
- 1 October 2000
- journal article
- clinical trial
- Published by Wiley in BJU International
- Vol. 86 (6) , 675-680
Abstract
Objective To assess the role of mitozantrone, active in relapsed prostate cancer, as an adjuvant to hormonal treatment in patients with advanced prostate cancer. Patients and methods Between October 1990 and May 1995, 96 patients were entered into a stratified, randomized, single‐institution study of hormonal therapy with a luteinizing hormone‐releasing hormone agonist and flutamide, with or without four cycles of adjuvant mitozantrone. Of these, 93 patients were evaluable and the results were analysed in June 1999. Results Patients with localized prostate cancer receiving adjuvant chemotherapy had a higher initial objective response rate (95% vs 53%, P = 0.008) and median survival (80 vs 36 months, P = 0.04) than patients who were treated with hormonal therapy alone. There was no advantage to adjuvant chemotherapy in patients with metastatic prostate cancer. There were insignificant advantages to chemotherapy in overall response rates (55% vs 39%, P = 0.3) and PSA responses (82% vs 64%, P = 0.11). There was no difference between the patient groups in time to treatment failure. Conclusion There was a survival advantage in using adjuvant mitozantrone in patients with locally advanced prostate cancer. Although the study comprised relative few patients, the follow‐up period was long and the advantage significant. We recommend that the study be extended to include more patients.Keywords
This publication has 12 references indexed in Scilit:
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- The diagnosis, management, treatment and costs of prostate cancer in England and Wales.Health Technology Assessment, 1997
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1996
- Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report.Journal of Clinical Oncology, 1994
- Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study.Journal of Clinical Oncology, 1990
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancerUrology, 1986
- Adjuvant chemotherapy for stage D1 adenocarcinoma of prostateUrology, 1983
- Chemotherapy of advanced prostatic cancer Evaluation of response parametersUrology, 1976